Advanced search
Publication Cover
OncoImmunology Volume 5, 2016 - Issue 8
Submit an article Journal homepage
2,433
Views
30
CrossRef citations to date
0
Altmetric
Original Research

Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction

Djoke HendriksUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, the Netherlands
,
Yuan HeUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, the Netherlands
,
Iris KoopmansUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, the Netherlands
,
Valerie R. WiersmaUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, the Netherlands
,
Robert J. van GinkelUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, the Netherlands
,
Douwe F. SamploniusUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, the Netherlands
,
Wijnand HelfrichUniversity of Groningen, University Medical Center Groningen (UMCG), Department of Surgery, Laboratory for Translational Surgical Oncology, Groningen, the NetherlandsCorrespondence[email protected]
&
Edwin BremerUniversity of Exeter Medical School, St Luke's Campus, Exeter, Devon, UK;University of Groningen, University Medical Center Groningen, Department of Experimental Hematology, Section Immunohematology, Cancer Research Center Groningen (CRCG), Groningen, the NetherlandsCorrespondence[email protected]
 show all
Article: e1202390 | Received 21 Mar 2016, Accepted 12 Jun 2016, Published online: 06 Jul 2016

Citations (30)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Yongxun Zhuan-Sun, Fengting Huang, Min Feng, Xinbao Zhao, Wenying Chen, Zhe Zhu & Shineng Zhang. (2017) Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis. OncoTargets and Therapy 10, pages 5005-5012.
Read now

Articles from other publishers (29)

Julio M. Pimentel, Jun-Ying Zhou & Gen Sheng Wu. (2023) The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer. Cancers 15:10, pages 2752.
Crossref
Julio M. Pimentel, Jun‐Ying Zhou & Gen Sheng Wu. (2022) Regulation of programmed death ligand 1 (PD‐L1) expression by TNF‐related apoptosis‐inducing ligand (TRAIL) in triple‐negative breast cancer cells. Molecular Carcinogenesis 62:2, pages 135-144.
Crossref
Alina Isakova, Artem Artykov, Yekaterina Vorontsova, Dmitry Dolgikh, Mikhail Kirpichnikov, Marine Gasparian & Anne Yagolovich. (2022) Application of an Autoinduction Strategy to Optimize the Heterologous Production of an Antitumor Bispecific Fusion Protein Based on the TRAIL Receptor-Selective Mutant Variant in Escherichia coli. Molecular Biotechnology.
Crossref
Kevin Chih-Yang Huang, Shu-Fen Chiang, Hsin-Yu Chang, William Tzu-Liang Chen, Pei-Chen Yang, Tsung-Wei Chen, Ji-An Liang, An‑Cheng Shiau, Tao-Wei Ke & K. S. Clifford Chao. (2022) Engineered sTRAIL-armed MSCs overcome STING deficiency to enhance the therapeutic efficacy of radiotherapy for immune checkpoint blockade. Cell Death & Disease 13:7.
Crossref
Weinan Guo, Zhenjie Wu, Jianru Chen, Sen Guo, Weiming You, Sijia Wang, Jinyuan Ma, Huina Wang, Xiangxu Wang, Hao Wang, Jingjing Ma, Yuqi Yang, Yangzi Tian, Qiong Shi, Tianwen Gao, Xiuli Yi & Chunying Li. (2022) Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis. Journal for ImmunoTherapy of Cancer 10:6, pages e004381.
Crossref
Vesna Risso, Elodie Lafont & Matthieu Le Gallo. (2022) Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases. Cell Death & Disease 13:3.
Crossref
Dong-Ho Geum, Dae-Seok Hwang, Chang-Hun Lee, Sung-Dae Cho, Min-A Jang, Mi-Heon Ryu & Uk-Kyu Kim. (2022) PD-L1 Expression Correlated with Clinicopathological Factors and Akt/Stat3 Pathway in Oral SCC. Life 12:2, pages 238.
Crossref
Huanyu Zhang, Guohui Qin, Chaoqi Zhang, Huiyun Yang, Jinyan Liu, Hongwei Hu, Peng Wu, Shasha Liu, Li Yang, Xinfeng Chen, Xueke Zhao, Lidong Wang & Yi Zhang. (2021) TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Xiaoyuan Yang, Xuelin Xia, Xiao-Xia Xia, Zhao Sun & Deyue Yan. (2021) Improving Targeted Delivery and Antitumor Efficacy with Engineered Tumor Necrosis Factor-Related Apoptosis Ligand-Affibody Fusion Protein. Molecular Pharmaceutics 18:10, pages 3854-3861.
Crossref
Chunjing Wu, Min You, Dao Nguyen, Medhi Wangpaichitr, Ying-Ying Li, Lynn G. Feun, Macus T. Kuo & Niramol Savaraj. (2021) Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma. International Journal of Molecular Sciences 22:14, pages 7628.
Crossref
Martin Snajdauf, Klara Havlova, Jiri VachtenheimJr.Jr., Andrej Ozaniak, Robert Lischke, Jirina Bartunkova, Daniel Smrz & Zuzana Strizova. (2021) The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. Frontiers in Molecular Biosciences 8.
Crossref
Shima Bastaki, Surendar Aravindhan, Nasrin Ahmadpour Saheb, Mahsa Afsari Kashani, Aleksei Evgenievich Dorofeev, Fariba Karoon Kiani, Hediyeh Jahandideh, Farzaneh Beigi Dargani, Mohsen Aksoun, Afshin Nikkhoo, Ali Masjedi, Ata Mahmoodpoor, Majid Ahmadi, Sanam Dolati, Simin Namvar Aghdash & Farhad Jadidi-Niaragh. (2021) Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice. Life Sciences 266, pages 118847.
Crossref
Ludovic Peyre, Mickael Meyer, Paul Hofman & Jérémie Roux. (2020) TRAIL receptor-induced features of epithelial-to-mesenchymal transition increase tumour phenotypic heterogeneity: potential cell survival mechanisms. British Journal of Cancer 124:1, pages 91-101.
Crossref
David Deng & Khalid Shah. (2020) TRAIL of Hope Meeting Resistance in Cancer. Trends in Cancer 6:12, pages 989-1001.
Crossref
Varun Vijay Prabhu, Sara Morrow, Abed Rahman Kawakibi, Lanlan Zhou, Marie Ralff, Jocelyn Ray, Aakash Jhaveri, Isacco Ferrarini, Young Lee, Cassandra Parker, Yiqun Zhang, Robyn Borsuk, Wen-I Chang, Joshua N. Honeyman, Fabio Tavora, Benedito Carneiro, Alexander Raufi, Kelsey Huntington, Lindsey Carlsen, Anna Louie, Howard Safran, Attila A. Seyhan, Rohinton S. Tarapore, Lee Schalop, Martin Stogniew, Joshua E. Allen, Wolfgang Oster & Wafik S. El-Deiry. (2020) ONC201 and imipridones: Anti-cancer compounds with clinical efficacy. Neoplasia 22:12, pages 725-744.
Crossref
Rui Liang, Yuanfei Yao, Guangyu Wang, Er Yue, Guangchao Yang, Xiuying Qi, Yang Wang, Ling Zhao, Tongsen Zheng, Yanqiao Zhang & Edward Wenge Wang. (2020) Repositioning Quinacrine Toward Treatment of Ovarian Cancer by Rational Combination With TRAIL. Frontiers in Oncology 10.
Crossref
Hassan Dianat-Moghadam, Maryam Heidarifard, Amir Mahari, Mehdi Shahgolzari, Mohsen Keshavarz, Mohammad Nouri & Zohreh Amoozgar. (2020) TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. Pharmacological Research 155, pages 104716.
Crossref
Man-Chin Chen, Christian Ronquillo Pangilinan & Che-Hsin Lee. (2019) Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression. Cancers 12:1, pages 57.
Crossref
Wei Wang & Junyan Tan. (2019) Co‐inhibition of BET proteins and PD‐L1 as a potential therapy for OSCC through synergistic inhibition of FOXM1 and PD‐L1 expressions. Journal of Oral Pathology & Medicine 48:9, pages 817-825.
Crossref
Wajant. (2019) Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation. Cancers 11:7, pages 954.
Crossref
Xinji Zhang, Xiaojun Shi, Jinlong Li, Zhiming Hu, Jimin Gao, Shihao Wu & Zhaolin Long. (2019) Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma. Cancer Science 110:1, pages 31-39.
Crossref
Yesi Shi, Xin Pang, Junqing Wang & Gang Liu. (2018) NanoTRAIL-Oncology: A Strategic Approach in Cancer Research and Therapy. Advanced Healthcare Materials 7:11, pages 1800053.
Crossref
Xiaojun Shi, Xinji Zhang, Jinlong Li, Lijun Mo, Hongfan Zhao, Yongtong Zhu, Zhiming Hu, Jimin Gao & Wanlong Tan. (2017) PD‐1 blockade enhances the antitumor efficacy of GM‐CSF surface‐modified bladder cancer stem cells vaccine. International Journal of Cancer 142:10, pages 2106-2117.
Crossref
Zakareya Gamie, Konstantinos Kapriniotis, Dimitra Papanikolaou, Emma Haagensen, Ricardo Da Conceicao Ribeiro, Kenneth Dalgarno, Anja Krippner-Heidenreich, Craig Gerrand, Eleftherios Tsiridis & Kenneth Samora Rankin. (2017) TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data. Cancer Letters 409, pages 66-80.
Crossref
Cinzia Solinas, Soizic Garaud, Pushpamali De Silva, Anaïs Boisson, Gert Van den Eynden, Alexandre de Wind, Paolo Risso, Joel Rodrigues Vitória, François Richard, Edoardo Migliori, Grégory Noël, Hugues Duvillier, Ligia Craciun, Isabelle Veys, Ahmad Awada, Vincent Detours, Denis Larsimont, Martine Piccart-Gebhart & Karen Willard-Gallo. (2017) Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. Frontiers in Immunology 8.
Crossref
Agathe Dubuisson & Olivier Micheau. (2017) Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy. Antibodies 6:4, pages 16.
Crossref
Yuan He, Peter E. van Bommel, Douwe F. Samplonius, Edwin Bremer & Wijnand Helfrich. (2017) A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members. Scientific Reports 7:1.
Crossref
Xiaojun Shi, Xinji Zhang, Jinlong Li, Hongfan Zhao, Lijun Mo, Xianghua Shi, Zhiming Hu, Jimin Gao & Wanlong Tan. (2017) PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer. Cancer Letters.
Crossref
D. Hendriks, G. Choi, M. de Bruyn, V.R. Wiersma & E. Bremer. 2017. 289 383 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.